Which has higher earnings and valuation, CTXR or XRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A

Is CTXR or XRTX more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% XORTX Therapeutics N/A -150.01% -106.53%

Do analysts recommend BIVI or XRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BIVI or XRTX?

BioVie is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A

Is BIVI or XRTX more profitable?

BioVie's return on equity of -101.15% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% XORTX Therapeutics N/A -150.01% -106.53%

Do analysts recommend BLRX or XRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XRTX or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, XRTX or PHIO?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is XRTX or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Phio Pharmaceuticals N/A -77.34% -70.87%

Do analysts rate XRTX or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 284.62%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XRTX or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Kiora Pharmaceuticals N/A -59.30% -41.23%

XORTX Therapeutics (XRTX) Competitors

$2.08 +0.02 (+0.97%)

Closing price 06/23/2026 03:45 PM Eastern

Extended Trading

$2.12 +0.04 (+1.92%)

As of 04:55 AM Eastern

Compare

XRTX vs. CTXR, BIVI, BLRX, PHIO, and KPRX

Should you buy XORTX Therapeutics stock or one of its competitors? MarketBeat compares XORTX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XORTX Therapeutics include Citius Pharmaceuticals (CTXR), BioVie (BIVI), BioLineRx (BLRX), Phio Pharmaceuticals (PHIO), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "med - drugs" industry.

How does XORTX Therapeutics compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Citius Pharmaceuticals' return on equity of -61.09% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
XORTX Therapeutics	N/A	-150.01%	-106.53%

Citius Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 792.86%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A

Citius Pharmaceuticals has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Citius Pharmaceuticals' average media sentiment score of 0.00 equaled XORTX Therapeutics'average media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
XORTX Therapeutics	Neutral

Summary

Citius Pharmaceuticals beats XORTX Therapeutics on 9 of the 11 factors compared between the two stocks.

How does XORTX Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVI) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

BioVie is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioVie's return on equity of -101.15% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
XORTX Therapeutics	N/A	-150.01%	-106.53%

BioVie has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

4.6% of BioVie shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioVie's average media sentiment score of 0.00 equaled XORTX Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioVie	Neutral
XORTX Therapeutics	Neutral

Summary

BioVie and XORTX Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does XORTX Therapeutics compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, BioLineRx had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for XORTX Therapeutics. BioLineRx's average media sentiment score of 0.00 equaled XORTX Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
XORTX Therapeutics	Neutral

XORTX Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
XORTX Therapeutics	N/A	-150.01%	-106.53%

BioLineRx has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioLineRx has higher revenue and earnings than XORTX Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.07	-$1.17M	-$1.92	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A

Summary

BioLineRx beats XORTX Therapeutics on 8 of the 11 factors compared between the two stocks.

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

XORTX Therapeutics (NASDAQ:XRTX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.00 equaled Phio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
XORTX Therapeutics	Neutral
Phio Pharmaceuticals	Neutral

Phio Pharmaceuticals' return on equity of -77.34% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

XORTX Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Phio Pharmaceuticals beats XORTX Therapeutics on 10 of the 12 factors compared between the two stocks.

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

XORTX Therapeutics (NASDAQ:XRTX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
XORTX Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

XORTX Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Kiora Pharmaceuticals	$16.02M	0.72	-$10.84M	-$2.71	N/A

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 284.62%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -59.30% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Summary

Kiora Pharmaceuticals beats XORTX Therapeutics on 8 of the 13 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export

Metric	XORTX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.57M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.79	18.43	24.66	23.99
Price / Sales	N/A	326.44	527.00	106.82
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.39	4.11	10.75	6.50
Net Income	-$2.66M	$64.45M	$3.56B	$336.88M
7 Day Performance	-3.26%	1.41%	1.00%	-0.14%
1 Month Performance	-4.59%	1.04%	0.43%	0.77%
1 Year Performance	-51.06%	23.88%	29.69%	28.49%

XORTX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XRTX XORTX Therapeutics	0.4645 of 5 stars	$2.08 +1.0%	N/A	-52.3%	$3.57M	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	2.3454 of 5 stars	$0.55 +1.2%	$5.00 +815.1%	-45.6%	$14.82M	N/A	N/A	20
BIVI BioVie	0.3567 of 5 stars	$1.76 -1.7%	N/A	-80.8%	$13.50M	N/A	N/A	10	Gap Down
BLRX BioLineRx	0.2899 of 5 stars	$3.16 +4.6%	N/A	-18.5%	$13.19M	$1.18M	N/A	40	Positive News
PHIO Phio Pharmaceuticals	2.8737 of 5 stars	$1.03 -4.6%	$14.00 +1,259.2%	-52.3%	$12.55M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CTXR, BIVI, BLRX, PHIO, and KPRX

How does XORTX Therapeutics compare to Citius Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to BioVie?

Summary

How does XORTX Therapeutics compare to BioLineRx?

Summary

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CTXR, BIVI, BLRX, PHIO, and KPRX

How does XORTX Therapeutics compare to Citius Pharmaceuticals?

Do institutionals and insiders have more ownership in CTXR or XRTX?

Is CTXR or XRTX more profitable?

Do analysts recommend CTXR or XRTX?

Which has higher earnings and valuation, CTXR or XRTX?

Which has more risk and volatility, CTXR or XRTX?

Does the media prefer CTXR or XRTX?

Summary

How does XORTX Therapeutics compare to BioVie?

Which has stronger earnings and valuation, BIVI or XRTX?

Do analysts recommend BIVI or XRTX?

Is BIVI or XRTX more profitable?

Which has more risk & volatility, BIVI or XRTX?

Do institutionals & insiders believe in BIVI or XRTX?

Does the media prefer BIVI or XRTX?

Summary

How does XORTX Therapeutics compare to BioLineRx?

Does the media prefer BLRX or XRTX?

Is BLRX or XRTX more profitable?

Which has more volatility & risk, BLRX or XRTX?

Do analysts recommend BLRX or XRTX?

Do institutionals and insiders believe in BLRX or XRTX?

Which has better valuation and earnings, BLRX or XRTX?

Summary

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

Do analysts recommend XRTX or PHIO?

Does the media favor XRTX or PHIO?

Is XRTX or PHIO more profitable?

Which has more volatility and risk, XRTX or PHIO?

Which has higher valuation and earnings, XRTX or PHIO?

Do institutionals & insiders have more ownership in XRTX or PHIO?

Summary

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

Do institutionals and insiders hold more shares of XRTX or KPRX?

Does the media favor XRTX or KPRX?

Which has stronger earnings and valuation, XRTX or KPRX?

Do analysts rate XRTX or KPRX?

Which has more risk and volatility, XRTX or KPRX?

Is XRTX or KPRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools